急性肾损伤患者使用碳酸氢钠与死亡率的关系:边际结构Cox模型分析
本研究利用美国重症监护数据库(MIMIC)中贝斯以色列女执事医疗中心多个ICU的数据,纳入急性肾损伤(KDIGO分期≥1)且至少一次pH≤7.2的酸中毒患者3406例,其中836例(24.5%)接受了静脉碳酸氢钠治疗。采用边际结构Cox模型,以pH、PaCO2、肌酐和碳酸氢根浓度作为时变预测因子,并调整年龄、性别、SOFA评分、AKI分期、Elixhauser评分、qSOFA和SAPS II等基线特征。结果显示,碳酸氢钠治疗与总体住院死亡率无显著关联(HR 1.16;95%CI 0.98-1.42;p=0.132),但在胰腺炎亚组(HR 0.53;95%CI 0.28-0.98;p=0.044)和重度酸中毒(pH<7.15)亚组(HR 0.75;95%CI 0.58-0.96;p=0.024)中似乎有益,在重度碳酸氢根缺失(<-50 kg·mmol/L)患者中也似乎有益。结论认为,调整潜在混杂因素后,无证据表明静脉碳酸氢钠对急性肾损伤合并酸中毒患者有益,亚组潜在获益需在实验性试验中验证。
要点
- 在急性肾损伤合并酸中毒的ICU患者中,静脉碳酸氢钠治疗与住院死亡率无显著关联(HR 1.16;95%CI 0.98-1.42;p=0.132)。
- 接受碳酸氢钠治疗的患者病情更重:SOFA评分更高(9 vs 7;p<0.001),pH更低(7.16 vs 7.18;p<0.001),碳酸氢根浓度更低(16.51±7.04 vs 20.57±6.29 mmol/L;p<0.001)。
- 在胰腺炎亚组中,碳酸氢钠治疗似乎有益(HR 0.53;95%CI 0.28-0.98;p=0.044)。
- 在重度酸中毒(pH<7.15)亚组中,碳酸氢钠治疗似乎有益(HR 0.75;95%CI 0.58-0.96;p=0.024)。
- 在重度碳酸氢根缺失(<-50 kg·mmol/L)患者中,碳酸氢钠似乎有益。
适用人群与场景
- 纳入标准:KDIGO急性肾损伤分期≥1(>1.5倍基线肌酐)且至少一次酸中毒测量(pH≤7.2)的ICU患者。
- 数据来源:美国贝斯以色列女执事医疗中心的多个ICU,包括冠状动脉监护室、心脏外科恢复室、内科ICU、外科ICU和创伤神经ICU。
诊断标准与关键阈值
- 急性肾损伤诊断标准:KDIGO分期≥1,即肌酐>1.5倍基线值;基线肌酐采用慢性肾脏病流行病学合作(CKD-EPI)方程估算。
- 酸中毒标准:pH≤7.2。
- 重度酸中毒亚组:pH<7.15。
- 重度碳酸氢根缺失亚组:<-50 kg·mmol/L。
研究设计与关键结果
- 研究设计:回顾性数据库分析,使用边际结构Cox模型,以pH、PaCO2、肌酐和碳酸氢根浓度作为时变预测因子,并调整年龄、性别、SOFA评分、AKI分期、Elixhauser评分、qSOFA和SAPS II等基线特征。
- 样本量:3406例 eligible 患者,其中836例(24.5%)接受静脉碳酸氢钠治疗。
- 主要终点:碳酸氢钠治疗与住院死亡率无显著关联(HR 1.16;95%CI 0.98-1.42;p=0.132)。
- 亚组结果:胰腺炎亚组HR 0.53(95%CI 0.28-0.98;p=0.044);重度酸中毒(pH<7.15)亚组HR 0.75(95%CI 0.58-0.96;p=0.024);重度碳酸氢根缺失(<-50 kg·mmol/L)患者中似乎有益。
- 基线特征比较:碳酸氢钠组 vs 未用碳酸氢钠组:SOFA评分9 vs 7(p<0.001);pH 7.16 vs 7.18(p<0.001);碳酸氢根浓度16.51±7.04 vs 20.57±6.29 mmol/L(p<0.001)。
证据类型、等级与局限
- 证据类型:基于大型重症监护数据库的回顾性队列研究,采用边际结构Cox模型分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急性肾损伤合并酸中毒的ICU患者中,静脉碳酸氢钠治疗与住院死亡率无显著关联。
- 在胰腺炎和重度酸中毒(pH<7.15)亚组中,碳酸氢钠似乎有益,但作者认为这些结果需在实验性试验中验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Acute kidney injury with metabolic acidosis is common in critically ill patients. This study assessed the associations between the use of IV sodium bicarbonate and mortality of patients with acute kidney injury and acidosis.
DESIGN: The study was conducted by using data from Beth Israel Deaconess Medical Center, which included several ICUs such as coronary care unit, cardiac surgery recovery unit, medical ICU, surgical ICU, and trauma-neuro ICU. Marginal structural Cox model was used to assess the relationship between receipt of sodium bicarbonate and hospital mortality, allowing pH, PaCO2, creatinine, and bicarbonate concentration as time-varying predictors of sodium bicarbonate exposure while adjusting for baseline characteristics of age, gender, Sequential Organ Failure Assessment score, acute kidney injury stage, Elixhauser score, quick Sequential Organ Failure Assessment, and Simplified Acute Physiology Score II.
SETTING: A large U.S.-based critical care database named Medical Information Mart for Intensive Care.
PATIENTS: Patients with Kidney Disease: Improving Global Outcomes acute kidney injury stage greater than or equal to 1 (> 1.5 (Equation is included in full-text article.)baseline creatinine) and one measurement of acidosis (pH ≤ 7.2). Baseline creatinine was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of the 3,406 eligible patients, 836 (24.5%) had received sodium bicarbonate treatment. Patients who received sodium bicarbonate treatment had a higher Sequential Organ Failure Assessment (9 vs 7; p < 0.001), lower pH (7.16 vs 7.18; p < 0.001), and bicarbonate concentration (16.51 ± 7.04 vs 20.57 ± 6.29 mmol/L; p < 0.001) compared with those who did not receive sodium bicarbonate. In the marginal structural Cox model by weighing observations with inverse probability of receiving sodium bicarbonate, sodium bicarbonate treatment was not associated with mortality in the overall population (hazard ratio, 1.16; 95% CI, 0.98-1.42; p = 0.132), but it appeared to be beneficial in subgroups of pancreatitis (hazard ratio, 0.53; 95% CI, 0.28-0.98; p = 0.044) and severe acidosis (pH < 7.15; hazard ratio, 0.75; 95% CI, 0.58-0.96; p = 0.024). Furthermore, sodium bicarbonate appeared to be beneficial in patients with severe bicarbonate deficit (< -50 kg·mmol/L).
CONCLUSIONS: In the analysis by adjusting for potential confounders, there is no evidence that IV sodium bicarbonate is beneficial for patients with acute kidney injury and acidosis. Although the study suggested potential beneficial effects in some highly selected subgroups, the results need to be validated in experimental trials.
参考来源
- Zhang Z, Mo L, Ho KM, et al. Association Between the Use of Sodium Bicarbonate and Mortality in Acute Kidney Injury Using Marginal Structural Cox Model. Crit Care Med. 2019. PMID: 31356473. doi:10.1097/CCM.0000000000003927
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。